|
**Overview**: Prostate Health Screen Panel**Introduction**: The Prostate Health Screen Panel is a diagnostic tool designed to screen for prostate health using serum samples. In India, prostate cancer screening with PSA is recommended for high-risk men (>50 years or family history), with free/total PSA ratio improving specificity. High morbidity from under-screening in rural/low-SES elderly men, limited labs, delayed detection of localized disease leading to advanced presentation or metastasis. Per urology practices aligned with ICMR and Urological Society of India guidelines, the test employs immunoassay for total PSA, free PSA, and PSA ratio over 1-2 days with high accuracy, valuable for initial risk assessment and biopsy decision. This diagnostic falls under cancer screening and targets men >50 years or symptomatic (LUTS, hematuria), addressing accurate detection to guide further evaluation or surveillance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early prostate health screening and reducing late-stage burden. Its serum-based approach ensures reliable PSA profiling.**Other Names**: Prostate Scr Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/oncology, compliant with 2025 standards.**Historical Milestone**: PSA screening standard; in India, expanding in geriatric/urology care.**Purpose**: The test assesses 3 parameters including total PSA to guide prostate health screening, assess risk, inform biopsy.**Test Parameters**: 1. Total PSA, 2. Free PSA, 3. PSA Ratio.**Pretest Condition**: Fasting 10-12 hours recommended; patients should avoid ejaculation/DRE.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on urinary symptoms, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected cancer including progression, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent DRE can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated total PSA/low free/total ratio indicates high risk, necessitating specialist input.**Specialist Consultation**: Urologists should be consulted for management.**Additional Supporting Tests**: DRE, mpMRI for confirmation.**Test Limitations**: Not diagnostic; comprehensive approach required.**References**: Indian Journal of Urology 2024, Prostate Studies India 2023. |
